PRLD
Prelude Therapeutics Incorporated
NASDAQ · Healthcare · Biotechnology · US
$5.46
+4.00%Year over year
Reported trailing growth
- Revenue
- +220.3%
- EBITDA
- +54.6%
- EBIT
- +50.1%
- EPS
- +51.8%
- Free cash flow
- +69.4%
- Operating cash flow
- +69.3%
Forward estimates
Based on analyst estimates
- Revenue
- +113.3%
- EBITDA
- +44.9%
- EPS
- +52.7%
Three-year CAGR
- Revenue
- +73.4%
- EBITDA
- +22.0%
- EBIT
- +25.2%
- Net income
- +21.8%
- EPS
- +23.2%
- Free cash flow
- +45.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026